復星醫藥(02196.HK)子公司產品不合格
復星醫藥(02196.HK)公布,中國藥監局發布《國家藥監局關於83批次藥品不符合規定的通告(2019年第75號)》,經遼寧省藥品檢驗檢測院抽檢,控股子公司蘇州二葉生產的一批次產品不符合規定。公司表示,有關產品於2018年度及2019年上半年的銷售收入分別約為7,000萬元人民幣(下同)及6,200萬元,分別佔同期營業收入之0.3%及0.4%,對公司之正常生產經營未造成實質性影響。
公司並指,管理層對此高度重視,已要求蘇州二葉就產品生產過程進行全面覆查並及時完成整改,並督促各成員企業以此次事件為誡,進一步加強藥品生產質量的全過程管理,持續提升產品全生命周期的質量風險管理水平,防止此類情況再次發生,又指蘇州二葉已根據蘇州市市場監督管理局的要求完成整改。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.